Abstract
This report provides recommendations for use of a newly developed recombinant outer-surface protein A (rOspA) Lyme disease vaccine (LYMErix, SmithKline Beecham Pharmaceuticals) for persons aged 15-70 years in the United States. The purpose of these recommendations is to provide health-care providers, public health authorities, and the public with guidance regarding the risk for acquiring Lyme disease and the role of vaccination as an adjunct to preventing Lyme disease. The Advisory Committee on Immunization Practices recommends that decisions regarding vaccine use be made on the basis of assessment of individual risk, taking into account both geographic risk and a person's activities and behaviors relating to tick exposure.
Publication types
-
Guideline
-
Practice Guideline
MeSH terms
-
Adolescent
-
Adult
-
Antibodies, Bacterial / biosynthesis
-
Antigens, Surface / administration & dosage*
-
Antigens, Surface / adverse effects
-
Antigens, Surface / economics
-
Bacterial Outer Membrane Proteins / administration & dosage*
-
Bacterial Outer Membrane Proteins / adverse effects
-
Bacterial Outer Membrane Proteins / economics
-
Bacterial Vaccines / administration & dosage*
-
Bacterial Vaccines / adverse effects
-
Bacterial Vaccines / economics
-
Borrelia burgdorferi Group / immunology*
-
Cost-Benefit Analysis
-
Humans
-
Lipoproteins
-
Lyme Disease / economics
-
Lyme Disease / epidemiology
-
Lyme Disease / prevention & control*
-
Middle Aged
-
Risk Factors
-
United States
-
Vaccination / economics
-
Vaccination / standards*
Substances
-
Antibodies, Bacterial
-
Antigens, Surface
-
Bacterial Outer Membrane Proteins
-
Bacterial Vaccines
-
Lipoproteins
-
OspA protein